在急性卒中神经重症患者中验证波动性精神状态评估(FMSE)
本研究为前瞻性验证研究,在学术医学中心神经重症监护病房纳入139例神经重症卒中患者(平均年龄63.9岁,NIHSS中位数11分),由专家每日进行基于DSM-5的谵妄评估,训练有素的临床医生配对进行FMSE评估。共分析717个非昏迷配对评估日,其中52%被专家评为谵妄日,53%的患者至少一天出现谵妄。FMSE总体准确性高(AUC 0.85,95%CI 0.82-0.87);FMSE≥1分敏感性86%、特异性74%,≥2分敏感性70%、特异性88%;在失语和觉醒度下降患者中准确性仍高。阳性FMSE预测出院和3个月功能结局的AUC分别为0.86和0.85。作者认为FMSE是神经重症卒中患者准确的谵妄筛查工具,≥1分提示「可能」谵妄(优先敏感性),≥2分提示「很可能」谵妄(优先特异性)。
要点
- FMSE是一种专为神经重症患者开发的谵妄筛查工具,在139例卒中患者、717个非昏迷评估日中,与专家DSM-5评估相比总体AUC为0.85(95%CI 0.82-0.87)。
- FMSE≥1分:敏感性86%、特异性74%,适用于优先保证敏感性的场景(提示「可能」谵妄)。
- FMSE≥2分:敏感性70%、特异性88%,适用于优先保证特异性的场景(提示「很可能」谵妄)。
- 在失语患者中FMSE≥1分敏感性82%、特异性64%,≥2分敏感性64%、特异性84%;在觉醒度下降患者中≥1分敏感性87%、特异性77%,≥2分敏感性71%、特异性90%。
- 阳性FMSE评估预测出院功能结局AUC 0.86(95%CI 0.79-0.93),预测3个月功能结局AUC 0.85(95%CI 0.78-0.92)。
适用人群与场景
- 神经重症监护病房的急性卒中患者,共139例,平均年龄63.9岁(SD 15.9),NIHSS评分中位数11分(IQR 2-17)。
- 分析限于非昏迷日,共717个配对评估日。
诊断标准与关键阈值
- 谵妄诊断金标准为精神科专家每日依据《精神障碍诊断与统计手册》第五版(DSM-5)进行的评估。
- FMSE≥1分提示「可能」谵妄,适用于优先保证敏感性的情况(敏感性86%、特异性74%)。
- FMSE≥2分提示「很可能」谵妄,适用于优先保证特异性的情况(敏感性70%、特异性88%)。
研究设计与关键结果
- 研究设计:前瞻性验证研究,在学术医学中心神经重症监护病房进行,纳入139例神经重症卒中患者,无干预。
- 共分析717个非昏迷配对评估日,其中52%(n=373)被专家评为谵妄日;53%的患者至少一天出现谵妄。
- FMSE总体准确性高:AUC 0.85(95%CI 0.82-0.87)。
- FMSE≥1分:敏感性86%、特异性74%;FMSE≥2分:敏感性70%、特异性88%(基于每次评估)。
- 失语患者:FMSE≥1分敏感性82%、特异性64%;FMSE≥2分敏感性64%、特异性84%。
- 觉醒度下降患者:FMSE≥1分敏感性87%、特异性77%;FMSE≥2分敏感性71%、特异性90%。
- 阳性FMSE预测出院功能结局AUC 0.86(95%CI 0.79-0.93),预测3个月功能结局AUC 0.85(95%CI 0.78-0.92)。
证据类型、等级与局限
- 证据类型:前瞻性验证研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为FMSE是神经重症卒中患者准确的谵妄筛查工具。
- 作者建议FMSE≥1分用于提示「可能」谵妄并优先保证敏感性,FMSE≥2分用于提示「很可能」谵妄并优先保证特异性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Neurocritically ill patients are at high risk for developing delirium, which can worsen the long-term outcomes of this vulnerable population. However, existing delirium assessment tools do not account for neurologic deficits that often interfere with conventional testing and are therefore unreliable in neurocritically ill patients. We aimed to determine the accuracy and predictive validity of the Fluctuating Mental Status Evaluation (FMSE), a novel delirium screening tool developed specifically for neurocritically ill patients.
DESIGN: Prospective validation study.
SETTING: Neurocritical care unit at an academic medical center.
PATIENTS: One hundred thirty-nine neurocritically ill stroke patients (mean age, 63.9 [ sd , 15.9], median National Institutes of Health Stroke Scale score 11 [interquartile range, 2-17]).
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Expert raters performed daily Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition-based delirium assessments, while paired FMSE assessments were performed by trained clinicians. We analyzed 717 total noncomatose days of paired assessments, of which 52% ( n = 373) were rated by experts as days with delirium; 53% of subjects were delirious during one or more days. Compared with expert ratings, the overall accuracy of the FMSE was high (area under the curve [AUC], 0.85; 95% CI, 0.82-0.87). FMSE scores greater than or equal to 1 had 86% sensitivity and 74% specificity on a per-assessment basis, while scores greater than or equal to 2 had 70% sensitivity and 88% specificity. Accuracy remained high in patients with aphasia (FMSE ≥ 1: 82% sensitivity, 64% specificity; FMSE ≥ 2: 64% sensitivity, 84% specificity) and those with decreased arousal (FMSE ≥ 1: 87% sensitivity, 77% specificity; FMSE ≥ 2: 71% sensitivity, 90% specificity). Positive FMSE assessments also had excellent accuracy when predicting functional outcomes at discharge (AUC, 0.86 [95% CI, 0.79-0.93]) and 3 months (AUC, 0.85 [95% CI, 0.78-0.92]).
CONCLUSIONS: In this validation study, we found that the FMSE was an accurate delirium screening tool in neurocritically ill stroke patients. FMSE scores greater than or equal to 1 indicate "possible" delirium and should be used when prioritizing sensitivity, whereas scores greater than or equal to 2 indicate "probable" delirium and should be used when prioritizing specificity.
参考来源
- Reznik ME, Margolis SA, Andrews N, et al. Validating the Fluctuating Mental Status Evaluation in Neurocritically Ill Patients With Acute Stroke. Crit Care Med. 2024. PMID: 39365697. doi:10.1097/CCM.0000000000006437
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。